Shares of Indoco Remedies are likely to remain in focus after the company said its solid oral dosage manufacturing facility (Plant I) in Goa has received EU Good Manufacturing Practice (GMP) certification from the Malta Medicines Authority.
The certification follows an inspection conducted by the regulator between November 19 and November 24, 2025, and confirms that the facility complies with the Good Manufacturing Practice (GMP) requirements under the relevant European Commission Directive.
Commenting on the development, Managing Director Aditi Panandikar said the compliance is a core value that drives our quality systems. This approval reinforces our commitment to delivering highest quality healthcare to our customers worldwide
Catch all the market action on our live blog
In the month of May, the company received EU GMP certification from the German Health Authority (Berlin) for its Oral Solid Dosage (OSD) manufacturing facility (Plant III) located at Baddi, Himachal Pradesh.
The inspection was carried out from April 22 to 27, 2026, confirms that the facility complies with Good Manufacturing Practice requirements as referred in the EC Directive.